Peptide

FGL Peptide

Also known as

FG Loop · NCAM mimetic · FGL peptide

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	An experimental synthetic peptide modeled on NCAM, a brain-cell protein involved in nerve connections. It is discussed for learning, memory and mood.
Forms and routes	FGL, nasal-study FGLL and hyaluronate-modified HA-FGL are different preparations. Nasal and SubQ reports cannot be converted directly into one dose or effect picture.

Notes

FGL is an experimental peptide discussed for learning, memory and mood. A few reports describe easier learning or sharper recall; other accounts, especially involving HA-FGL, describe brain fog or worsened mood. Different forms and routes complicate the picture, and human cognitive benefit remains unproven.

A signal copied from a brain-cell protein. FGL is a synthetic peptide modeled on part of NCAM, a protein involved in connections between nerve cells. Researchers study whether it helps those connections adapt during learning. AMPA receptors mentioned in forums are receivers for nerve signals; changing them in rats does not demonstrate better human memory. It is not an organ-extract bioregulator. Facilitation of AMPA Receptor Synaptic Delivery as a Molecular Mechanism for Cognitive Enhancement (Animal context · Accessed 2026-09-30)

FGL, FGLL and HA-FGL need separate identities. Forum contributors warn that “FGL” covers different preparations. FGLL is the form in the human nasal study; HA-FGL adds hyaluronate, a large sugar-based molecule intended to change delivery. A report using one form cannot establish another form’s dose or effects. NA-FGL form and unit discussion (Community discussion · Accessed 2026-09-30) · HA-FGL discussion (Secondhand community claim · Accessed 2026-09-30)

Nasal and injected reports are different. Intranasal means through the nose; subcutaneous means under the skin. Both occur in self-experiments. Neither provides an established human regimen, and the milligrams in a FGLL study cannot be converted directly into a microgram injection amount.

Source context — Facilitation of AMPA Receptor Synaptic Delivery as a Molecular Mechanism for Cognitive Enhancement: Animal and tissue findings; not human cognitive effectiveness.

Source context — NA-FGL form and unit discussion: Includes seller speculation; routes and frequency incomplete.

Source context — HA-FGL discussion: Mechanistic discussion; no first-person outcomes.

What people notice

Learning and mood	One injected-FGL user described easier learning and a mood lift without standardized testing. A nasal account claimed stronger recall after a week.
HA-FGL reports	A seller relayed worsened thinking, anxiety, low mood and brain fog, alongside one later report of a cognitive boost. These are mixed, secondhand accounts with unconfirmed identity.
Focus claims	Attention, motivation and mental fatigue recur in discussion. A study-focus recommendation without an experience log does not demonstrate better concentration.

Notes

Easier learning and a mood lift. LongeCity user Xenix described these changes during an injected FGL experiment. This was a subjective account without standardized testing; it does not show a reliable effect for other people. Xenix’s FGL experiment (Personal report · Accessed 2026-09-30)

One nasal account: after a week. Tobeornottobe claimed strong recall then; same-day onset remains unknown. FGL peptide experiences/info (Community discussion · Accessed 2026-09-30)

The memory story remains one account. Tobeornottobe’s potency claim and later update are one person; no objective test verifies photographic memory. FGL peptide experiences/info (Community discussion · Accessed 2026-09-30)

HA-FGL had mixed, secondhand reports. The seller relayed worsened thinking, anxiety, low mood and brain fog, plus one account later reporting a cognitive boost. Material identity was unconfirmed. FGL peptide experiences/info (Community discussion · Accessed 2026-09-30)

Sharper recall attracts attention. A Reddit study-focus discussion recommends FGL for short-term memory, but supplies no FGL experience log. That is an endorsement, not evidence that it improves concentration or lets someone learn faster. Peptides for focus and study enhancement (Community opinion · Accessed 2026-09-30)

Brain fog and motivation are part of the appeal. Community notes also mention attention, mental fatigue, motivation and anxiety changes. Sleep, caffeine and other stimulants complicate these impressions; feeling more motivated is different from demonstrating stronger memory.

Source context — Xenix’s FGL experiment: Anonymous self-report; unverified preparation; no standardized tests.

Source context — FGL peptide experiences/info: Anonymous reports; HA-FGL seller testimony is secondhand and commercial; no verified identity.

Source context — Peptides for focus and study enhancement: Recommendation only; no FGL course or measured benefit.

Doses people talk about

Injected FGL account	250 mcg SubQ twice daily: 500 mcg, or 0.5 mg, total per day. The precise preparation was not established; this is one account.
Nasal accounts	One poster claimed 0.5 mg ordinary FGL with frequency unstated. A seller separately estimated 10–40 mcg for nasal HA-FGL. Neither establishes a daily standard.
FGLL study	25, 100 or 200 mg intranasally once in a small safety/PK study, not a cognition regimen. A forum's 200 mg versus 200 mcg mix-up is a 1,000-fold error.

Notes

Injected FGL: 250 mcg twice daily in one account. Xenix reported subcutaneous use: 250 micrograms per administration, totaling 500 mcg (0.5 mg) daily. The material’s precise form was not established. This is one self-experiment, not a community standard. Xenix’s FGL experiment (Personal report · Accessed 2026-09-30)

Nasal FGL: 0.5 mg claimed. Tobeornottobe called this a starting amount. Frequency was unstated; it is not a known daily total. FGL peptide experiences/info (Community discussion · Accessed 2026-09-30)

HA-FGL: estimated 10–40 mcg. A seller proposed this for the modified nasal form before reporting mixed results. Effectiveness was not measured. FGL peptide experiences/info (Community discussion · Accessed 2026-09-30)

FGLL: 25, 100 or 200 mg intranasally once. The 2007 study followed 24 healthy men over eight days for tolerability and blood levels. It did not test cognitive benefit, repeated use, or safety in pregnancy or breastfeeding. Anand et al.: intranasal FGLL tolerability and blood levels (Official context · Accessed 2026-09-30)

A thousandfold unit error appears in a forum. One contributor mistook the FGLL study’s 200 mg for 200 mcg. The correction matters: those units differ by 1,000. Neither number establishes a self-use dose. NA-FGL form and unit discussion (Community discussion · Accessed 2026-09-30)

Source context — Xenix’s FGL experiment: Anonymous self-report; unverified preparation; no standardized tests.

Source context — FGL peptide experiences/info: Anonymous reports; HA-FGL seller testimony is secondhand and commercial; no verified identity.

Source context — Anand et al.: intranasal FGLL tolerability and blood levels: Abstract only; subscription full text not inspected; small open-label male single-dose study.

Source context — NA-FGL form and unit discussion: Includes seller speculation; routes and frequency incomplete.

Half-life, onset & duration

Felt onset	The injected account reported a checkpoint around ten days; a nasal account claimed recall changes after one week. Neither times the onset of a single dose.
Felt duration	No reliable human effect window is established. A circulated three-day claim comes from animal memory work.
Half-life	No dependable human half-life is established here. FGLL blood detection through one or four hours after different nasal study amounts is not an elimination half-life.

Notes

Around ten days in the injected account. That was Xenix’s first reported checkpoint, not a measured delay after each injection. Xenix’s FGL experiment (Personal report · Accessed 2026-09-30)

One nasal account: after a week. Tobeornottobe claimed strong recall then; same-day onset remains unknown. FGL peptide experiences/info (Community discussion · Accessed 2026-09-30)

No reliable human effect window. The forum’s “three days” claim derives from animal memory work, not a person timing their experience. It cannot tell us how long a nasal or injected dose feels active. FGL dose and timing disagreement (Secondhand community claim · Accessed 2026-09-30)

No dependable community human half-life. No human measurement of bodily removal appears in these reports. Detectability in blood does not measure how long the amount takes to halve. FGL dose and timing disagreement (Secondhand community claim · Accessed 2026-09-30)

Detection is different from half-life or felt duration. Blood measurements detected FGLL through one hour after 100 mg and four hours after 200 mg; 25 mg stayed below measurement limits. The accessible abstract gives no elimination half-life. These windows do not time memory benefits. Anand et al.: intranasal FGLL tolerability and blood levels (Official context · Accessed 2026-09-30)

Source context — Xenix’s FGL experiment: Anonymous self-report; unverified preparation; no standardized tests.

Source context — FGL peptide experiences/info: Anonymous reports; HA-FGL seller testimony is secondhand and commercial; no verified identity.

Source context — FGL dose and timing disagreement: Supplier interest; animal arithmetic and misquoted trial cohorts; no human timing measurements.

Source context — Anand et al.: intranasal FGLL tolerability and blood levels: Abstract only; subscription full text not inspected; small open-label male single-dose study.

Cycles people discuss

Reported exposure	The injected account describes use up to about ten days, not a completed repeating cycle or known break requirement.
Early stopping	One secondhand HA-FGL account stopped after two days amid fog and depression. No agreed repeat course emerges.

Notes

About ten days is a report, not a complete cycle. Xenix described use up to that point. Follow-up requests do not establish a course endpoint, necessary break or sustained benefit. Xenix’s FGL experiment (Personal report · Accessed 2026-09-30) · FGL follow-up questions (Community discussion · Accessed 2026-09-30)

One HA-FGL account stopped after two days. The seller relayed brain fog and depression with uncertain attribution. No agreed repeating course emerges. FGL peptide experiences/info (Community discussion · Accessed 2026-09-30)

Source context — Xenix’s FGL experiment: Anonymous self-report; unverified preparation; no standardized tests.

Source context — FGL follow-up questions: Quotes repeat Xenix; questions are not completed courses.

Source context — FGL peptide experiences/info: Anonymous reports; HA-FGL seller testimony is secondhand and commercial; no verified identity.

Stacks

Dihexa discussion	A proposed FGL/Dihexa combination has no completed experiment demonstrating synergy in the cited thread. Another thread raises an unverified nerve-cell-death concern.
Other nootropics	Semax, Selank and Cerebrolysin appear in comparison and stack talk; these mixed discussions do not establish added benefit or safe combinations.

Notes

Enthusiastic questions are not completed experiments. The Reddit FGL-and-Dihexa post asks about a combination and availability. It closely matches the LongeCity opening and supplies no completed experiment demonstrating synergy. FGL peptide experiences? (Community discussion · Accessed 2026-09-30)

Dihexa stacking raised concern. The thread warned of possible nerve-cell death from combining them. This unverified concern establishes neither synergy nor a safe waiting interval. FGL peptide experiences/info (Community discussion · Accessed 2026-09-30)

Nootropic comparison and stack talk: FGL or FGLL is discussed beside agents such as Dihexa, Semax, Selank, or Cerebrolysin, but sparse mixed-agent threads do not establish synergy or a protocol. [community]

Stacks make effects difficult to attribute. Other substances and sleep changes can obscure both benefit and harm. Comparing FGL with Semax, Selank or Cerebrolysin does not establish that combining them is safe or more effective.

Source context — FGL peptide experiences?: Some replies collapsed; dihexa replies must not become FGL outcomes.

Source context — FGL peptide experiences/info: Anonymous reports; HA-FGL seller testimony is secondhand and commercial; no verified identity.

Watch for

Mood and sleep	Mixed HA-FGL reports include depression, anxiety and fog. Insomnia at 2 mg ordinary FGL is a secondhand claim with route and frequency unclear.
Animal seizure finding	FGL lowered the electrical stimulation needed to trigger generalized seizures in mice. This does not measure human seizure risk or establish a safe threshold.
Identity and tolerability	Unknown impurities, allergy and injection-site reactions remain concerns. The small single-dose nasal trial reported brief burning or runny eyes and cannot establish long-term safety.

Notes

Insomnia has been relayed. A separate thread relays a secondhand claim of insomnia at 2 mg of ordinary FGL; it gives no dependable route or frequency. That cannot establish a threshold below which sleep is protected. NA-FGL form and unit discussion (Community discussion · Accessed 2026-09-30)

A mouse seizure study raises a separate warning. In electrically stimulated mice, FGL reduced the stimulation needed to trigger a generalized seizure. This is animal evidence, not a measured human seizure rate, but it argues against assuming a nerve-growth mechanism is automatically protective. Zellinger et al.: FGL in the mouse kindling model (Animal context · Accessed 2026-09-30)

Product and injection risks remain. The community record flags allergy, unknown impurities, redness, itching, lumps and bruising with injected products. Identity, purity and longer-term effects remain uncertain. Severe allergic symptoms, chest pain, new neurological symptoms or uncontrolled blood pressure or glucose need medical care.

Brief local irritation was reported. Two participants at 200 mg had nasal burning under three minutes; one at 25 mg had runny eyes under two minutes. Later dizziness, vomiting and headache were judged unrelated. This limited study cannot establish long-term safety. Anand et al.: intranasal FGLL tolerability and blood levels (Official context · Accessed 2026-09-30)

Source context — FGL peptide experiences/info: Anonymous reports; HA-FGL seller testimony is secondhand and commercial; no verified identity.

Source context — NA-FGL form and unit discussion: Includes seller speculation; routes and frequency incomplete.

Source context — Zellinger et al.: FGL in the mouse kindling model: Primary abstract reproduced via public API; full text not inspected.

Source context — Anand et al.: intranasal FGLL tolerability and blood levels: Abstract only; subscription full text not inspected; small open-label male single-dose study.

Full notes

What FGL is

A signal copied from a brain-cell protein. FGL is a synthetic peptide modeled on part of NCAM, a protein involved in connections between nerve cells. Researchers study whether it helps those connections adapt during learning. AMPA receptors mentioned in forums are receivers for nerve signals; changing them in rats does not demonstrate better human memory. It is not an organ-extract bioregulator. Animal context
FGL, FGLL and HA-FGL need separate identities. Forum contributors warn that “FGL” covers different preparations. FGLL is the form in the human nasal study; HA-FGL adds hyaluronate, a large sugar-based molecule intended to change delivery. A report using one form cannot establish another form’s dose or effects. LongeCity Reddit
Nasal and injected reports are different. Intranasal means through the nose; subcutaneous means under the skin. Both occur in self-experiments. Neither provides an established human regimen, and the milligrams in a FGLL study cannot be converted directly into a microgram injection amount. Community

Why people look it up

Easier learning and a mood lift. LongeCity user Xenix described these changes during an injected FGL experiment. This was a subjective account without standardized testing; it does not show a reliable effect for other people. Personal report
Sharper recall attracts attention. A Reddit study-focus discussion recommends FGL for short-term memory, but supplies no FGL experience log. That is an endorsement, not evidence that it improves concentration or lets someone learn faster. Reddit
Brain fog and motivation are part of the appeal. Community notes also mention attention, mental fatigue, motivation and anxiety changes. Sleep, caffeine and other stimulants complicate these impressions; feeling more motivated is different from demonstrating stronger memory. Community

Doses people discuss

Injected FGL: 250 mcg twice daily in one account. Xenix reported subcutaneous use: 250 micrograms per administration, totaling 500 mcg (0.5 mg) daily. The material’s precise form was not established. This is one self-experiment, not a community standard. Personal report
Nasal FGL: 0.5 mg claimed. Tobeornottobe called this a starting amount. Frequency was unstated; it is not a known daily total. LongeCity
HA-FGL: estimated 10–40 mcg. A seller proposed this for the modified nasal form before reporting mixed results. Effectiveness was not measured. LongeCity
A thousandfold unit error appears in a forum. One contributor mistook the FGLL study’s 200 mg for 200 mcg. The correction matters: those units differ by 1,000. Neither number establishes a self-use dose. LongeCity

Half-life

No dependable community human half-life. No human measurement of bodily removal appears in these reports. Detectability in blood does not measure how long the amount takes to halve. LongeCity

When people notice it

Around ten days in the injected account. That was Xenix’s first reported checkpoint, not a measured delay after each injection. Personal report
One nasal account: after a week. Tobeornottobe claimed strong recall then; same-day onset remains unknown. LongeCity

How long changes feel noticeable

No reliable human effect window. The forum’s “three days” claim derives from animal memory work, not a person timing their experience. It cannot tell us how long a nasal or injected dose feels active. LongeCity

Courses and breaks

About ten days is a report, not a complete cycle. Xenix described use up to that point. Follow-up requests do not establish a course endpoint, necessary break or sustained benefit. Personal report LongeCity
One HA-FGL account stopped after two days. The seller relayed brain fog and depression with uncertain attribution. No agreed repeating course emerges. LongeCity

Good to know

Dihexa stacking raised concern. The thread warned of possible nerve-cell death from combining them. This unverified concern establishes neither synergy nor a safe waiting interval. LongeCity
Insomnia has been relayed. A separate thread relays a secondhand claim of insomnia at 2 mg of ordinary FGL; it gives no dependable route or frequency. That cannot establish a threshold below which sleep is protected. LongeCity
A mouse seizure study raises a separate warning. In electrically stimulated mice, FGL reduced the stimulation needed to trigger a generalized seizure. This is animal evidence, not a measured human seizure rate, but it argues against assuming a nerve-growth mechanism is automatically protective. Animal context
Product and injection risks remain. The community record flags allergy, unknown impurities, redness, itching, lumps and bruising with injected products. Identity, purity and longer-term effects remain uncertain. Severe allergic symptoms, chest pain, new neurological symptoms or uncontrolled blood pressure or glucose need medical care. Community
Stacks make effects difficult to attribute. Other substances and sleep changes can obscure both benefit and harm. Comparing FGL with Semax, Selank or Cerebrolysin does not establish that combining them is safe or more effective. Community

What the human study actually checked

FGLL: 25, 100 or 200 mg intranasally once. The 2007 study followed 24 healthy men over eight days for tolerability and blood levels. It did not test cognitive benefit, repeated use, or safety in pregnancy or breastfeeding. Official context
Brief local irritation was reported. Two participants at 200 mg had nasal burning under three minutes; one at 25 mg had runny eyes under two minutes. Later dizziness, vomiting and headache were judged unrelated. This limited study cannot establish long-term safety. Official context
Detection is different from half-life or felt duration. Blood measurements detected FGLL through one hour after 100 mg and four hours after 200 mg; 25 mg stayed below measurement limits. The accessible abstract gives no elimination half-life. These windows do not time memory benefits. Official context

From community discussion

The memory story remains one account. Tobeornottobe’s potency claim and later update are one person; no objective test verifies photographic memory. LongeCity
HA-FGL had mixed, secondhand reports. The seller relayed worsened thinking, anxiety, low mood and brain fog, plus one account later reporting a cognitive boost. Material identity was unconfirmed. LongeCity
Calculations and testimonials did not agree. A supplier questioned low-dose anecdotes using animal-to-human arithmetic. That disagreement is real, but the calculation does not validate a higher human dose or invalidate a person’s subjective experience. LongeCity
Enthusiastic questions are not completed experiments. The Reddit FGL-and-Dihexa post asks about a combination and availability. It closely matches the LongeCity opening and supplies no completed experiment demonstrating synergy. Reddit
Social-media repair claims go beyond the evidence. A LinkedIn video promotes FGL for brain repair and rapid mood effects. It supplies no controlled human outcomes; the nasal safety study does not establish treatment of Alzheimer’s disease, brain injury or depression. LinkedIn Official context